TG Therapeutics, Inc.
$56.04 +$0.54 (+0.97%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
May 6
The stock moved +16.3% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 6 -
Mar 17
The stock moved +9.5% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 17
The story updates itself as events post · The wolf reports; you decide
Snapshot
About TG Therapeutics, Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.